Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hudcová

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Vnitrni Lekarstvi|May 30, 2013
[Changes in weight and diabetes compensation (HbA(1c)) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBY-I study (observations lasting 3 to 12 months)]J Perusicová, I Haladová, P Pit'hová, et al.
Vnitrni Lekarstvi|May 29, 2013
[Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic -  BIBYII study (observations lasting 24 months)]J Perušičová, P Piťhová, I Haladová, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|August 22, 2024
The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024)P Kleiblová, J Novotný, D Cibula, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|November 8, 2024
The guidelines for clinical practice for carriers of germline mutations in the Lynch syndrome predisposition genes MLH1, MSH2, MSH6, PMS2 and large deletions of EPCAM (4.2024)J Novotný, D Cibula, V Curtisová, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Vnitrni Lekarstvi|May 30, 2013
[Changes in weight and diabetes compensation (HbA(1c)) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBY-I study (observations lasting 3 to 12 months)]J Perusicová, I Haladová, P Pit'hová, et al.
Vnitrni Lekarstvi|May 29, 2013
[Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic -  BIBYII study (observations lasting 24 months)]J Perušičová, P Piťhová, I Haladová, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|August 22, 2024
The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024)P Kleiblová, J Novotný, D Cibula, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|November 8, 2024
The guidelines for clinical practice for carriers of germline mutations in the Lynch syndrome predisposition genes MLH1, MSH2, MSH6, PMS2 and large deletions of EPCAM (4.2024)J Novotný, D Cibula, V Curtisová, et al.
Pageof 1